Abstract
[Dmt1]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2; Dmt = 2′,6′-dimethyltyrosine) binds with high affinity and selectivity to the μ opioid receptor and is a surprisingly potent and long-acting analgesic, especially after intrathecal administration. In an attempt to better understand the unique pharmacological profile of [Dmt1]DALDA, we have prepared [3H][Dmt1]DALDA and compared its binding properties with that of [3H]DAMGO ([d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin). Kinetic studies revealed rapid association of [3H][Dmt1]DALDA when incubated with mouse brain membranes (K+1 = 0.155 nM–1 min–1). Dissociation of [3H][Dmt1]DALDA was also rapid (K–1 = 0.032 min–1) and indicated binding to a single site. [3H][Dmt1]DALDA binds with very high affinity to human μ opioid receptor (hMOR) (Kd = 0.199 nM), and Kd and Bmax were reduced by sodium but not Gpp(NH)p [guanosine 5′-(β,γ-imido)triphosphate]. Similar Kd values were obtained in brain and spinal cord tissues and SH-SY5Y cells. The hMOR:hDOR (human δ opioid receptor) selectivity of [Dmt1]DALDA (∼10,000) is 8-fold higher than DAMGO. However, [Dmt1]DALDA is less selective than DAMGO against hKOR (human κ opioid receptor) (26-versus 180-fold). The Ki values for a number of opioid ligands were generally higher when determined by competitive displacement binding against [3H][Dmt1]DALDA compared with [3H]DAMGO, with the exception of Dmt1-substituted peptide analogs. All Dmt1 analogs showed much higher affinity for the μ receptor than corresponding Tyr1 analogs. [35S]GTPγS (guanosine 5′-O -(3-[35S]thio)triphosphate) binding showed that [Dmt1]DALDA and DAMGO are full agonists at hMOR and hDOR but are only partial agonists at hKOR. The very high affinity and selectivity of [3H][Dmt1]DALDA for the μ receptor, together with its very low nonspecific binding (10–15%) and metabolic stability, make [3H][Dmt1]DALDA an ideal radioligand for labeling μ receptors.
Footnotes
-
This work was supported, in part, by a multicenter program project grant (DA08924) from the National Institute on Drug Abuse.
-
ABBREVIATIONS: hMOR, cloned human μ opioid receptor; hDOR, cloned human δ opioid receptor; hKOR, cloned human κ opioid receptor; [Dmt1]DALDA, H-Dmt-d-Arg-Phe-Lys-NH2; Dmt = 2′,6′-dimethyltyrosine; DAMGO, [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin; DSLET, [d-Ser2,Leu5]-enkephalin-Thr; Fmoc, N-(9-fluorenyl)methoxycarbonyl; U69,593, (5α,7α,8β)-(+)-N-methyl-N-(7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec-8-yl)-benzeneacetamide; GTPγS, guanosine 5′-O-(3-thio)triphosphate; DPDPE, [d-Pen2,d-Pen5]-enkephalin; U50,488H, [trans-(±)-3,4-dichloro-N-methyl-[2-(1-pyrolidinyl)-cyclohexyl] benzeneacetamide; HEK, human embryonic kidney; CHO, Chinese hamster ovary; Gpp(NH)p, guanosine 5′-(β,γ-imido)triphosphate.
-
DOI: 10.1124/jpet.103.054775.
- Received May 21, 2003.
- Accepted August 22, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|